Insulet Corporation(PODD)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Latest News & Analysis
Insulet's Automation Inflection: From Niche to Secular Growth
Q3 earnings beat and raised guidance signal that Omnipod 5 automation is delivering durable margin expansion while opening Type 2 diabetes TAM.
Insulet's Omnipod 5: European Expansion and Q4 Earnings Outlook
A data-driven analysis of Insulet (PODD)'s Omnipod 5 expansion in Europe and key metrics ahead of its Q4 2024 earnings report.
Insulet Q4 Earnings: Strong Revenue, Margins Amid Stock Decline
Insulet reported robust Q4 2024 earnings driven by Omnipod 5 and European expansion, yet stock declined due to softer future revenue guidance.
Insulet (PODD) Q4 2024: Earnings, Market Reaction, and Future Outlook
Insulet (PODD) Q4 2024 earnings beat estimates, driven by Omnipod 5. Despite this, PODD stock fell, raising investor concerns about future growth. A detailed analysis follows.
Insulet (PODD) Q4 2024 Earnings: Omnipod 5 Growth and Market Analysis
Insulet's Q4 2024 earnings beat expectations, driven by Omnipod 5 demand. Despite a stock dip, analysts see continued growth in the evolving diabetes market.
Insulet (PODD) Q4 2024 Earnings: Omnipod 5 Drives Growth, Competition Intensifies
Insulet's Q4 2024 earnings showcased strong revenue growth driven by Omnipod 5, but the stock price declined despite positive results. Competition intensifies.
Insulet (PODD) Q4 2024 Earnings: Growth, Challenges, and Outlook
Insulet's Q4 2024 earnings reveal growth, but EPS decline raises concerns. Omnipod 5 drives expansion, while competition and market trends present challenges.
Insulet (PODD) Q4 Earnings: Omnipod 5 Growth & Investor Day Preview
Insulet (PODD) surges +3.8% following strong Q4 earnings, fueled by Omnipod 5 adoption. Investor Day on June 5th to reveal future strategies.
Insulet (PODD): Debt Offering, Investor Day, and Omnipod's Market Impact
Insulet (PODD) navigates a dynamic landscape with a $450M debt offering, upcoming Investor Day, and sustained Omnipod demand, showcasing resilience and growth potential.
Insulet (PODD): Omnipod 5, RADIANT Trial, and Financial Strategy
Analysis of Insulet (PODD): Omnipod 5 adoption, RADIANT trial, $450M senior notes, and financial strategies shaping its growth and market position.
Insulet (PODD): Expansion, Debt Strategy, and Market Challenges
Insulet (PODD) navigates expansion, debt, and competition in automated insulin delivery. Australian launch, trial data, and a $450M note offering shape its trajectory.
Insulet (PODD): Omnipod 5 Expansion, Financial Outlook
Analysis of Insulet (PODD): Omnipod 5 expansion, financial health, and competitive landscape amidst macroeconomic headwinds. Key insights for investors.
Insulet (PODD) Financial Analysis: Dexcom G7 Integration & Q1 Growth
Insulet's Q1 2025 revenue surged by 29%, driven by strong Omnipod 5 adoption and the recent Dexcom G7 integration, positioning the company for continued growth.
Insulet Corporation (PODD) Market Analysis: Omnipod 5 Growth & Financial Performance
Explore Insulet's Omnipod 5 growth drivers, market expansion, Dexcom G7 integration, and robust 2025 financials shaping its diabetes technology leadership.
Insulet Corporation (PODD) Navigates Medicare Cuts Amid Strong Growth and Competitive Pressure
Insulet faces regulatory headwinds from Medicare reimbursement cuts impacting Omnipod 5 growth, while maintaining strong financials and navigating intense competition.
Insulet Corporation (PODD) Navigates Medicare Reimbursement Cuts Amid Strong Omnipod 5 Growth
Insulet faces Medicare reimbursement cuts impacting margins, but Omnipod 5 adoption and international expansion drive resilience and growth prospects.
Insulet Corporation (PODD) Market Update: Omnipod 5 Growth Amid Medicare Dynamics and Financial Strength
Insulet (PODD) shows strong Q1 2025 revenue growth driven by Omnipod 5 adoption, navigating Medicare reimbursement shifts with solid financials and strategic international expansion.
Insulet Corporation Q2 2025 Earnings & Market Analysis: Omnipod 5 Growth Amid Medicare Challenges
Insulet's Q2 2025 earnings preview highlights Omnipod 5's growth, Medicare reimbursement headwinds, and strategic financial metrics shaping investor outlook.
Insulet Corporation PODD Q2 Earnings Surge on Omnipod 5 Adoption Boosts Revenue and Margins
Insulet (PODD) posts strong Q2 earnings beat driven by Omnipod 5 adoption, raising full-year revenue and EPS forecasts, supported by expanding market share and innovation.
Insulet (PODD): Omnipod 5 Drives Fast Growth — Can Scale and Margins Keep Pace?
Insulet posted Q2 revenue growth of **+32.90%** and raised 2025 guidance; Omnipod 5, Type 2 clearance and pharmacy rollout underpin top-line acceleration amid high multiples.